LHDX - LHDX STOCK NEWS

Lucira Health welcomes Tony Allen as COO, enhancing its leadership team amid expansion efforts. Allen, with 25 years of operations experience, previously held significant roles at Ortho-Clinical Diagnostics, Alcon, and DJO Global. His appointment is seen as pivotal as Lucira aims to boost the production and availability of its innovative COVID-19 test kits. CEO Erik Engelson expressed optimism about Allen's contributions to streamline operations and increase global product access.

Lucira Health (NASDAQ: LHDX) has appointed Ghazi Kashmolah as Chief Quality Officer and Executive Vice President Regulatory Affairs. With over 30 years in quality and regulatory roles, Kashmolah's experience includes leadership positions at Orchid Orthopedic Solutions and Cardinal Health. His expertise is expected to enhance Lucira's consumer-friendly infectious disease test kits, particularly during the COVID pandemic. The company is focused on developing and commercializing innovative testing solutions, including its lab-quality molecular testing kits that provide results within 30 minutes.

Lucira Health (LHDX) reported a record-high revenue of $12.4 million for Q2 2021, marking a 175% sequential growth from Q1. The sales surge was driven by the LUCIRA CHECK IT COVID-19 Test Kit, available OTC without a prescription, supported by international demand. The company initiated operations at a new manufacturing center in the Dominican Republic to boost production capacity. However, it reported a GAAP net loss of $16.2 million for Q2, an increase from $6.6 million in the same period last year, amid rising operating expenses.

Lucira Health, a medical technology company, will report its second quarter 2021 financial results on August 12, 2021. The conference call will take place at 1:30 p.m. PT / 4:30 p.m. ET, featuring a discussion on the financial results and a corporate update. Lucira specializes in innovative infectious disease test kits that deliver PCR quality molecular testing using a single-use, consumer-friendly design. Their COVID-19 test kits provide reliable results within 30 minutes, aimed at enhancing accessibility to accurate testing.

Lucira Health, Inc. (Nasdaq: LHDX) announced the appointment of Kevin Collins as Chief Revenue Officer, responsible for global revenue. Collins has a strong background in medical technology, having previously worked with Intuitive Surgical and Outset Medical. CEO Erik Engelson expressed confidence in Collins' capacity to enhance sales and leverage Lucira’s innovative infectious disease testing platform. Lucira specializes in lab-quality, consumer-friendly test kits for diseases, offering rapid results, particularly for COVID-19.

Lucira Health (NASDAQ: LHDX), a leader in innovative infectious disease testing, will participate in the William Blair 41st Annual Growth Stock Conference on June 2, 2021, at 10:40 a.m. PT / 1:40 p.m. ET. The event can be accessed via a live and archived webcast on their official investor relations site.

Lucira specializes in creating consumer-friendly, lab-quality molecular testing kits, including the LUCIRA COVID-19 All-In-One Test Kit, which delivers results in just 30 minutes.

Lucira Health (NASDAQ: LHDX) reported its Q1 2021 financial results, revealing a net revenue of $4.5 million, driven by healthcare sales. The company incurred a GAAP net loss of $13.3 million, significantly higher than last year's $1.7 million loss. Key developments included receiving FDA EUA authorization for its OTC LUCIRA CHECK IT COVID-19 Test Kit, launching a partnership with the Golden State Warriors, and opening a manufacturing facility in the Dominican Republic, enhancing production capacity. Cash balance stood at $189.8 million.

Lucira Health, Inc. (LHDX) has launched its LUCIRA™ CHECK IT COVID-19 test kit on Amazon.com, enabling at-home PCR quality testing in under 30 minutes. Priced at $55 with free shipping, it offers a LUCI PASS digital result, which can be used for work and travel verification. The kit aims to simplify COVID-19 testing by providing a reliable, quick solution, with clinical trials demonstrating 98% accuracy compared to leading tests. Lucira's product is the first authorized OTC self-test in the U.S. and Canada.

Lucira Health (Nasdaq: LHDX), a medical technology company, will participate in the BofA Securities 2021 Virtual Healthcare Conference on May 13, 2021, at 9:30 a.m. PT / 12:30 p.m. ET. The event will be accessible via a live and archived webcast on Lucira's investor page. Lucira specializes in innovative infectious disease test kits that deliver lab-quality results within 30 minutes using user-friendly, battery-powered devices. Their test kits, including the LUCIRA CHECK IT and LUCIRA COVID-19 All-In-One Test Kits, aim to provide reliable testing anywhere.